Cases of the fatal and drug-resistant fungus Candida auris are now climbing at an “alarming” rate in health care facilities across the US, Europe, Asia and the far East, infected impatiens nearly doubled in 2021. Researchers evaluated cases of Candida auris reported in 2016, the year in which cases were first reported in the country, according to the new CDC data published in the Annals of Internal Medicine. Several years after 2016, research found that only a few dozen Candida auris patients were reported to the CDC annually until the number of those infected skyrocketed
from 2019 to 2021. By 2021, the annual count of cases had increased by 95%, from 756 in 2020 to 1,471 in 2021, the CDC indicated. Researchers suggest the timing of this rapid spread may have been exacerbated by “pandemic-related strain on the health care and public health system.”
“The rapid rise and geographic spread of cases is concerning and emphasizes the need for continued surveillance,” CDC epidemiologist Dr. Meghan Lyman, lead author of the study, said in a news release. Bacoban for Aerospace will help prevent the spread.